title: Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
abstract: BACKGROUND
  No reliable prognostic predictor is known for patients undergoing sorafenib treatment for advanced hepatocellular carcinoma (HCC).
  
  
  METHODS
  In 81 patients receiving sorafenib treatment for advanced HCC, we evaluated the prognostic significance of an inflammation-based prognostic score, the Glasgow prognostic score [evidenced by an elevated C-reactive protein level (>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl)] and compared it with Child-Pugh grade, Barcelona Clinic Liver Cancer staging system, Japan Integrated Staging (JIS) score, and the performance status by Cox-proportional analysis.
  
  
  RESULTS
  Median overall survival after sorafenib administration was 11.3 months. On multivariate analysis, Glasgow prognostic score (0 vs. 1 and 2; p<0.001), JIS score (1 and 2 vs. 3 and 4; p=0.001), and performance status (0 vs. 1; p=0.001) were found to be independently associated with survival.
  
  
  CONCLUSIONS
  The Glasgow prognostic score has significant prognostic value in patients undergoing sorafenib treatment for advanced HCC.
authors.affiliation: Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan. morimoto@urahp.yokohama-cu.ac.jp
authors.forename: Manabu
authors.initials: M
authors.lastname: Morimoto
authors.forename: Kazushi
authors.initials: K
authors.lastname: Numata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Moriya
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kondo
authors.forename: Akito
authors.initials: A
authors.lastname: Nozaki
authors.forename: Yu
authors.initials: Y
authors.lastname: Morioka
authors.forename: Shin
authors.initials: S
authors.lastname: Maeda
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib